A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Trial details
- Registry ID
- NCT06246110
- Phase
- Phase 2
The FDA approved Carboplatin (Paraplatin) on 3 Mar 1989.
Drug identity checked against registry records
Also recorded as Paraplatin
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1989-03-03Day | Carboplatin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA019880", "applicant_as_listed_by_fda": "CORDEN PHARMA", "brand_names": ["PARAPLATIN"], "active_ingredients": ["CARBOPLATIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19890303", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |